Literature DB >> 3182859

Comparative study of the asparagine-linked sugar chains of natural human interferon-beta 1 and recombinant human interferon-beta 1 produced by three different mammalian cells.

Y Kagawa1, S Takasaki, J Utsumi, K Hosoi, H Shimizu, N Kochibe, A Kobata.   

Abstract

The asparagine-linked sugar chains of natural interferon-beta 1 secreted from human foreskin fibroblasts by poly I:poly C induction and of three recombinant human interferon-beta 1 produced by Chinese hamster ovary cells, mouse epithelial cells (C127), and human lung adenocarcinoma cells (PC8) were released quantitatively as oligosaccharides by hydrazinolysis followed by N-acetylation. After being reduced with either NaB3H4 or NaB2H4, their structures were comparatively analyzed. More than 80% of the sugar chains of natural interferon-beta 1 occur as biantennary complex-type sugar chains, approximately 10% of which contain N-acetyllactosamine repeating structure in their outer chain moieties. The remainders are 2,4- and 2,6-branched triantennary complex-type sugar chains. The sugar chains of the recombinant interferon-beta 1 derived from Chinese hamster ovary cells were very similar to those of its natural counterpart. In contrast, two other recombinant proteins contain quite different sugar chains. The protein derived from C127 cells contains complex-type sugar chains with the Gal alpha 1----3Gal beta 1----4GlcNAc group in their outer chain moieties. Their sialic acid residues occur solely as the Sia alpha 2----6Gal group, where Sia is sialic acid. In contrast, the sialic acid residues of other interferon-beta 1 occur as the Sia alpha 2----3Gal group only. A part of the sugar chains of the protein derived from PC8 cells contains bisecting N-acetylglucosamine residue in addition to the Gal alpha 1----3Gal beta 1----4GlcNAc group.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3182859

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Building high affinity human antibodies by altering the glycosylation on the light chain variable region in N-acetylglucosamine-supplemented hybridoma cultures.

Authors:  H Tachibana; J Y Kim; S Shirahata
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

2.  Overexpression and biosynthesis of CD4 in Chinese hamster ovary cells: coamplification using the multiple drug resistance gene.

Authors:  R König; G Ashwell; J A Hanover
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

3.  Increased bisecting and core-fucosylated N-glycans on mutant human amyloid precursor proteins.

Authors:  Keiko Akasaka-Manya; Hiroshi Manya; Yoko Sakurai; Boguslaw S Wojczyk; Steven L Spitalnik; Tamao Endo
Journal:  Glycoconj J       Date:  2008-06-03       Impact factor: 2.916

4.  The use of UCOE vectors in combination with a preadapted serum free, suspension cell line allows for rapid production of large quantities of protein.

Authors:  Trish Benton; Tim Chen; Michele McEntee; Brian Fox; David King; Robert Crombie; Thomas C Thomas; Christopher Bebbington
Journal:  Cytotechnology       Date:  2002-01       Impact factor: 2.058

5.  Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta).

Authors:  L Runkel; W Meier; R B Pepinsky; M Karpusas; A Whitty; K Kimball; M Brickelmaier; C Muldowney; W Jones; S E Goelz
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

Review 6.  Antibody variable region glycosylation: biochemical and clinical effects.

Authors:  A Wright; S L Morrison
Journal:  Springer Semin Immunopathol       Date:  1993

7.  Identification of genes encoding N-glycan processing beta-N-acetylglucosaminidases in Trichoplusia ni and Bombyx mori: Implications for glycoengineering of baculovirus expression systems.

Authors:  Christoph Geisler; Donald L Jarvis
Journal:  Biotechnol Prog       Date:  2010 Jan-Feb

8.  Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: potential implications for protein aggregation and immunogenicity.

Authors:  Riccardo Torosantucci; Victor S Sharov; Miranda van Beers; Vera Brinks; Christian Schöneich; Wim Jiskoot
Journal:  Mol Pharm       Date:  2013-05-02       Impact factor: 4.939

Review 9.  Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody.

Authors:  U Galili
Journal:  Springer Semin Immunopathol       Date:  1993

Review 10.  Carbohydrate analysis throughout the development of a protein therapeutic.

Authors:  Elizabeth Higgins
Journal:  Glycoconj J       Date:  2009-11-04       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.